Arcera Life Sciences and Innogen Pharmaceuticals Sign Exclusive Licensing Agreement to Expand Access
Agreement marks a significant step in Arcera’s strategy to strengthen its cardiometabolic franchise and broaden its portfolio of innovative medicines across international markets.
Abu Dhabi, UAE / Hong Kong, China, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Arcera Life Sciences (“Arcera”), an international life sciences company headquartered in Abu Dhabi, UAE, and Innogen Pharmaceuticals (“Innogen”) (HKEX: 2591), a Shanghai-based biopharmaceutical company focused on metabolic diseases, today announced an exclusive licensing and commercialization agreement for Efsubaglutide Alfa, a GLP-1 receptor agonist therapy across key international markets, including the UAE.
The agreement brings together Innogen’s expertise in metabolic diseases with Arcera’s regulatory, market access and commercial capabilities, establishing cardiometabolic disease as a core pillar of Arcera’s portfolio. It also reflects Arcera’s ambition to be a partner of choice for bringing differentiated innovative medicines to patients in international markets.
Under the agreement, Arcera will be responsible for regulatory activities, market access and commercialization of the therapy across agreed territories spanning selected countries in Africa, Eastern Europe, Latin America and the Middle East. Innogen will receive an upfront payment and will be eligible for milestone payments and tiered royalties on net sales of the product in the licensed territories.

Cardiometabolic diseases, including obesity and type 2 diabetes, represent a substantial and growing healthcare burden globally. According to the International Diabetes Federation, 589 million adults worldwide are living with diabetes, a number projected to reach 853 million by 2050. This partnership between Arcera and Innogen is a step toward wider access to advanced metabolic therapies.
GLP-1 receptor agonists are a class of therapy used in the management of type 2 diabetes and, increasingly, obesity. In 2025, the World Health Organization added GLP-1 therapies to its Model List of Essential Medicines and issued a global guideline on their use in treating obesity, a condition affecting more than one billion people worldwide. For Arcera, the agreement strengthens its presence in this therapy area and creates a platform for further growth in cardiometabolic medicine across its international markets.
Efsubaglutide Alfa is a fusion protein comprising a human GLP-1 analogue and an IgG Fc fragment, with a half-life of up to 280 hours across different studies. Clinical studies showed HbA1c reductions of approximately 2.2 percentage points at Week 24. Clinical studies in Chinese adults with overweight or obesity showed that 18 weeks of treatment achieved average weight reductions of 10.6% with once-weekly (QW) dosing and 9.7% with once-every-two-weeks (Q2W) dosing.
The study also observed improvements in body-composition. The muscle-to-fat ratio increased by up to 45.3% from baseline with QW dosing, with weight loss driven predominantly by a reduction in fat mass, indicating fat reduction with relative preservation of muscle. Liver fat content was reduced by up to 51.8% with QW dosing. The incidence of gastrointestinal adverse events was low relative to other GLP-1 receptor agonists (based on cross-trial comparisons), no participants discontinued treatment due to adverse events during an 18-week treatment period, and the treatment was well tolerated. Innogen has also completed a Phase II clinical trial in adults with overweight or obesity in Australia, evaluating the efficacy and safety of once-monthly (Q4W) dosing. The study generated further clinical evidence to support the product’s future global registration and commercialization.
Isabel Afonso, Chief Executive Officer of Arcera Life Sciences, said: “Cardiometabolic diseases remain among the most pressing healthcare challenges in the markets we serve. Our agreement with Innogen accelerates the bridge we are building between China and our international markets to bring innovative medicines to more patients and strengthen our cardiometabolic portfolio. By combining our partners’ scientific capabilities with Arcera’s regulatory expertise, market access and overall commercial reach, we aim to turn innovation into meaningful impact for people living with chronic disease.”
Dr. Qinghua Wang, Founder, Chairman and Chief Executive Officer of Innogen Pharmaceuticals, said: “We are delighted to establish this collaboration with Arcera, which represents an important step in Innogen’s international expansion. We believe that combining world-class science with entrepreneurial innovation is key to improving patient care. Innogen’s mission is to provide best-in-class and first-in-class therapies for people living with diabetes, obesity and other metabolic diseases worldwide. Our collaboration with Arcera is an important step toward this vision. By combining Innogen’s scientific innovation with Arcera’s strengths in international regulatory affairs and commercialization, we aim to broaden access to differentiated therapies and ultimately improve the quality of life of patients around the world.”
The transaction is subject to the customary regulatory and operational requirements applicable in the relevant territories. Commercialization will begin following receipt of the required local regulatory approvals.
END
About Arcera Life Sciences
Arcera Life Sciences is an international life sciences company headquartered in Abu Dhabi, United Arab Emirates. Arcera brings innovative and proven medicines to patients in over 100 countries worldwide, with operations spanning Africa, Eurasia, Latin America, and the Middle East. Arcera commercializes medicines and healthcare products across multiple therapeutic areas, supported by manufacturing and packaging capabilities in eight countries. To expand access to innovative therapies, Arcera partners with leading pharmaceutical and biotech companies, ensuring supply resilience and quality standards. Its portfolio comprises over 2,000 product presentations marketed under 300+ brands in more than 60 direct markets. To learn more about Arcera, visit www.arceralifesciences.com.
About Innogen Pharmaceuticals
Founded in 2014, Innogen Pharmaceuticals (HKEX: 2591) is a biopharmaceutical company focused on the research, development and industrialization of innovative medicines for metabolic diseases. The Company has a wholly self-developed pipeline covering indications including type 2 diabetes (T2D), type 1 diabetes (T1D), obesity, metabolic dysfunction-associated steatohepatitis (MASH) and Alzheimer’s disease (AD), supported by global intellectual property rights and a global patent portfolio. Its core product, Efsubaglutide Alfa, is a next-generation, human-derived, ultra-long-acting GLP-1 receptor agonist developed in-house. It has been approved for the treatment of T2D in mainland China and Macao, China, and has been included in China’s National Reimbursement Drug List (2025 Version). Development of the product received support under China’s 13th Five-Year Plan Major New Drug Innovation program. It has also received the First Prize of the Science and Technology Award of the Chinese Pharmaceutical Association and the First Prize of the Science and Technology Award of the Shanghai Pharmaceutical Association. Innogen has entered the stage of global development and regulatory registration, and its manufacturing facilities have obtained PIC/S GMP certification. The Company is committed to providing better treatment options for patients worldwide. For more information, please visit www.innogenpharm.com.
Attachments
- 浓情脱身,为爱前行!锁定今晚重庆卫视#脱身#大结局!
- Blockmate Launches Bitcoin Treasury Division in Line with “Mine-and-Hold” Strategy
- 私护进入“抗衰时间”:Dr. Good新品精华油把“以油养肤”带进私密护理
- 世贸通移民集团:身份规划助力企业出海,走向世界!
- 拜耳梨树耘远农场:农达®助力生物育种产业化与再生农业协同发展
- Visa Reimagines Payment Acceptance for the ‘Click-and-Mortar' Era
- A123首款半固态浸没式储能全系列产品即将发布
- 第二届广西茶宴文化节即将盛大启幕,“四美”融合绽放八桂茶香
- Sandoz enters global collaboration license agreement with Henlius
- Fortinet Reports First Quarter 2025 Financial Results
- 798元/㎡高定专享LSB-5芯板!从“卷价格”到“立标准”,顾家家居想在整家赛道走更远
- 思秉自动化:领航的装箱式机械手解决方案
- 一碗螺蛳粉串起南北烟火 泉城小店绘就民生产业新图景
- 宝利化荣获发明专利,创新实力再获认可
- Esentia宣布成功完成2033年到期的6.125%优先票据和2038年到期的6.500%优先票据的定价
- 林芝交付,远程超级VAN以新高度、新深度、新宽度开启客运未来
- 光明乳业:用数字力量支撑中国乳业高质量发展
- 丝所扎根静安沃土,双向赋能共谱丝绸新篇
- 王鹤棣演唱会即将泰国开唱,从原点走向未来,兑现与粉丝之约
- 农发行郴州市分行直营部:2.24亿金融活水润泽“希望田”
- ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia
- 拉斯海玛酋长为首家拉斯海玛在华商务咨询机构揭幕,深化与广东的合作
- 党建护航银龄生活 瑞众保险探索“保险+”服务新路径
- Moore Nanotechnology Systems (Nanotech) 将被Shibaura Machine Group收购,共同组建一家新的超精密机床企业
- SS2026北京时装周邂逅玫瑰:合玉坊演绎东方优雅新章
- 夏日聚会美味贡乃烤鸡 香嫩多汁带来好心情
- 复星的全球化之路 创造了真正的稀缺性
- 匠心服务 大爱如涛
- 专研高端护肤产品,315诚信品牌天仙子生物获权威认可
- Mesmerise与Mayo Clinic合作以改革医学教育和医护人员培训






